clinical trial · NCT04713982
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Vanderbilt University Medical Center·phase3·active not recruiting·n = 30
Huntington DiseaseDeutetrabenazine
brief summary
Examine the effects of deutetrabenazine on functional speech and gait impairment
started
Nov 19, 2021
primary completion
Jun 30, 2026
completion
Oct 1, 2026
last updated
Apr 14, 2026
detailed description
This is a two-year, prospective, single-arm study examining the effects of deutetrabenazine on functional speech and gait impairment. Participants will undergo comprehensive evaluations of speech production, fine motor skills, gait, and balance both before and after the initiation of deutetrabenazine. The investigators will utilize a variety of standardized, well-validated assessments as well as 3D motion analysis of both speech and gait parameters to determine the functional impact of deutetrabenazine on speech and motor performance.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol